Unlike FASN and leptin, sirtuin 2 (Sirt2) and the peroxisome proliferator-activated receptors alpha and gamma (PPAR-α/γ) are known to improve obesity-associated metabolic disorders and are considered therapeutic targets for diseases such as T2DM. This evidence concerns the gene PPARA and metabolic disease.